Research a compound stack end to end — a structured protocol scaffold, how VialTalk researchers actually combine these compounds, receptor conflicts, and live COA-verified prices. Add 1–5 compounds.
Research signals
Redundancy, true conflicts, and dangerous additive effects
Conflicts found
1 flagged interaction found
Receptor activity map
| Receptor | Retatrutide | GHK-Cu | Tirzepatide | Cagrilintide |
|---|---|---|---|---|
| GLP-1R (GLP1R, P43220) | ||||
| GIPR (P48546) | ||||
| GCGR (P47871) | ||||
| Amylin receptors (AMY1R, AMY2R, AMY3R) via CALCR-RAMP complexes | ||||
| Calcitonin receptor (CTR / CALCR, P30988) | ||||
| Extracellular matrix / copper-enzyme / MMP axis |
A structured, research-grounded protocol for this stack
Sign in to build a structured research protocol scaffold for Cagrilintide + Retatrutide + Tirzepatide + GHK-Cu — phases, per-compound parameters, endpoints and washout, grounded in documented research.
What VialTalk researchers actually run
No researchers have logged this exact combination yet — yours could be the first.
Researchers are also adding
Best price for each compound today
Same “From” price shown on each compound's page (after discounts). Panels = COA assays tested. Tap “Compare all vendors” for the full breakdown.
For research and informational use only. VialTalk does not provide medical advice or dosing guidance. Community data reflects self-reported public research journals.